Showing results (1601-1610 of 6,770) with videos related to

Sort By:
Pageof 677
Clinical Therapeutics|January 1, 1995
Methods of cost-effectiveness analysis: areas of consensus and debateB R Luce, K Simpson
Clinical Therapeutics|March 25, 2004
Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United KingdomAndrew J Palmer, Stéphane Roze, William J Valentine, et al.
Clinical Therapeutics|June 6, 2006
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT)Jarir Atthobari, Folkert W Asselbergs, Cornelis Boersma, et al.
Clinical Therapeutics|May 25, 2026
Time-Driven Activity-Based-Costing to Improve Healthcare Resource Use: Patient Pathways and Cost Comparisons for Cardiac Electrophysiology Interventions and Surgical Aortic Valve Replacement in Five Italian HospitalsAlberto Ricci, Marianna Cavazza, Giuditta Callea, et al.
Clinical Therapeutics|May 16, 2026
From Oxidative Stress to Pain Modulation With Melatonin in Neonatal and Pediatric CareSerafina Perrone, Laura Cannavò, Sofia Gerevini, et al.
Clinical Therapeutics|April 24, 2026
Lumacaftor-Ivacaftor in Pediatric Patients With Cystic Fibrosis and Advanced Liver Disease: A Pilot StudyAdeline Y L Lim, Maria P Hernández-Mitre, Peter J Lewindon, et al.
Clinical Therapeutics|May 15, 2026
Assessing the Potential Clinical Drug-Drug Interactions Between D-1553 (Garsorasib) and CYP450 Enzymes/Transporters via a Cocktail ApproachQian Chen, Qichen Ding, Chan Sun, et al.
Clinical Therapeutics|May 28, 2014
Exosomes as immunotheranostic nanoparticlesNatasha G, Buket Gundogan, Aaron Tan, et al.
Clinical Therapeutics|January 1, 1989
Improved skin adherence and patient acceptance in a new transdermal nitroglycerin delivery systemA J Hougham, R W Hawkinson, J K Crowley, et al.
Clinical Therapeutics|February 19, 2018
Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureusJames A McKinnell, Shelby Corman, Dipen Patel, et al.
Pageof 677